Market Cap: $40.93B
II
Illumina, Inc.
ILMN
NASDAQ (NASDAQ Global Select)USD
Market Cap: $40.93B
Illumina Inc (Ticker: ILMN) reinforces its commitment to innovation and growth by expanding its board of directors, adding esteemed pharmaceutical expert Daniel M. Skovronsky, M.D., Ph.D. With his exp…
Illumina strengthens its leadership in genomics with the recent appointment of Dr. Daniel M. Skovronsky (MD, PhD) to its Board of Directors, effective June 16, 2026. As the Chief Scientific and Produc…
Illumina (Ticker: ILMN) strengthens its leadership in the genomics space with the recent appointment of Dr. Daniel M. Skovronsky to its Board of Directors. This strategic move reflects the company's o…
Illumina Inc (Ticker: ILMN) continues to push the boundaries of genomic research with the launch of its StrataMap Spatial Solution, a cutting-edge platform that enhances sequencing-based spatial trans…
In a strategic move to enhance its offerings in the oncology sequencing sector, Illumina, Inc. (Ticker: ILMN) forges a significant partnership with Integrated DNA Technologies (IDT). This collaboratio…
Illumina Inc (Ticker: ILMN) strengthens its commitment to oncology with the recent launch of a novel molecular residual disease (MRD) research kit. Announced on May 28, 2026, this solution is the firs…
Illumina Inc. (Ticker: ILMN) has published its 2025 Corporate Responsibility Report, highlighting its dedication to enhancing global access to genomics and achieving ambitious sustainability milestone…
Illumina Welcomes New Leadership Ahead of Shareholders' Meeting Illumina, Inc. announces notable changes to its Board of Directors as it gears up for its annual shareholders' meeting scheduled for lat…
Illumina and the Rise of AI-Driven Oncology Solutions Illumina, a leader in genomic sequencing technologies, finds itself at the forefront of a rapidly evolving healthcare landscape, particularly in o…
Illumina and Labcorp Join Forces to Transform Precision Oncology On March 18, 2026, Illumina, Inc. and Labcorp announced a significant enhancement to their collaboration, focusing on revolutionizing p…
### Advancing Preventive Healthcare: Illumina's Collaboration with Veritas Genetics Illumina, Inc. recently announces a strategic collaboration with Veritas Genetics, backed by Fuze Health, that aims…
Illumina and Veritas Forge a New Path in Preventive Genomics In a groundbreaking initiative, Illumina, Inc. partners with Veritas Genetics, supported by Fuze Health, to integrate whole-genome sequenci…
Illumina Partners with Veritas Genetics to Redefine Preventive Genomics Illumina, Inc. announces a pivotal partnership with Veritas Genetics, facilitated by Fuze Health, aimed at revolutionizing the i…
Illumina's Alliance for Genomic Discovery Expands with Key Collaborations Illumina, Inc. advances its mission to revolutionize patient care through its Alliance for Genomic Discovery (AGD) by announci…
Illumina and Nashville Biosciences Forge New Frontiers in Genomic Research Illumina, Inc. and Nashville Biosciences, LLC announce a pivotal expansion of the Alliance for Genomic Discovery (AGD), a col…
Illumina and Nashville Biosciences Expand Genomic Discovery Alliance Illumina, Inc. collaborates with Nashville Biosciences, LLC to announce pivotal advancements in the Alliance for Genomic Discovery…
Illumina Partners with Florida Institute for Pediatric Rare Diseases to Enhance Diagnostics Illumina, Inc. announces a significant collaboration with the Florida Institute for Pediatric Rare Diseases…
Illumina Advances Oncology Research with Multiomics Solutions At the AGBT conference on February 25, 2026, Illumina, Inc. showcases transformative breakthroughs in oncology research through its innova…
Revolutionizing Genetic Analysis: Illumina's TruPath™ Genome Launch Illumina, Inc. introduces the TruPath™ Genome, a cutting-edge solution in whole genome sequencing that promises to transform the lan…
Illumina Innovates the NovaSeq X System to Enhance Sequencing Efficacy Illumina unveils an ambitious 18-month roadmap for its NovaSeq X system, targeting a range of innovations designed to significant…
Illumina unveils 18-month NovaSeq X upgrade roadmap Illumina is rolling out an 18-month roadmap of software, chemistry and consumable upgrades for its NovaSeq X high-throughput sequencer, aiming to bo…
Headline: Illumina maps 18-month upgrade cadence to boost NovaSeq X capacity and accuracy NovaSeq X upgrade plan targets higher throughput and Q70 accuracy Illumina unveils an 18-month roadmap of soft…
Illumina leans on clinical NGS momentum and SomaLogic deal Guidance and acquisition shape 2026 growth plan Illumina is positioning revenue growth for fiscal 2026 around expanding clinical uptake of ne…
Illumina links Frozen Zoo’s five-decade archive to modern genomics Illumina is announcing a large-scale sequencing collaboration with the San Diego Zoo Wildlife Alliance’s Frozen Zoo, aiming to conver…
Illumina Launches Groundbreaking Billion Cell Atlas to Transform Drug Discovery Illumina, Inc. has unveiled the Billion Cell Atlas, the world’s largest genome-wide genetic perturbation dataset, markin…